Medipharm Labs Corp
TSX:LABS
Medipharm Labs Corp
TSX:LABS
Price:
0.09
CAD
20%
Market Closed
Market Cap:
37.9m
CAD
Balance Sheet
Balance Sheet Decomposition
Medipharm Labs Corp
Medipharm Labs Corp
| Current Assets | 31.8m |
| Cash & Short-Term Investments | 8.4m |
| Receivables | 7.8m |
| Other Current Assets | 15.6m |
| Non-Current Assets | 20.3m |
| PP&E | 18.8m |
| Intangibles | 809k |
| Other Non-Current Assets | 635k |
Balance Sheet
Medipharm Labs Corp
Medipharm Labs Corp
Currency: CAD
Millions
Annual
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
8
|
39
|
20
|
34
|
24
|
18
|
12
|
|
| Cash Equivalents |
8
|
39
|
20
|
34
|
24
|
18
|
12
|
|
| Total Receivables |
6
|
28
|
34
|
17
|
13
|
6
|
8
|
|
| Accounts Receivables |
6
|
26
|
28
|
16
|
12
|
6
|
7
|
|
| Other Receivables |
0
|
1
|
6
|
1
|
1
|
0
|
1
|
|
| Inventory |
9
|
52
|
22
|
11
|
8
|
10
|
9
|
|
| Other Current Assets |
3
|
2
|
5
|
4
|
2
|
3
|
5
|
|
| Total Current Assets |
27
|
120
|
82
|
66
|
47
|
37
|
33
|
|
| PP&E Net |
14
|
42
|
34
|
26
|
18
|
25
|
19
|
|
| PP&E Gross |
14
|
42
|
34
|
26
|
18
|
25
|
19
|
|
| Accumulated Depreciation |
1
|
4
|
16
|
25
|
25
|
27
|
23
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
7
|
2
|
1
|
0
|
1
|
1
|
|
| Total Assets |
43
N/A
|
169
+295%
|
118
-30%
|
92
-22%
|
66
-29%
|
64
-2%
|
54
-16%
|
|
| Liabilities | ||||||||
| Accounts Payable |
8
|
19
|
6
|
3
|
4
|
2
|
4
|
|
| Accrued Liabilities |
1
|
3
|
9
|
4
|
4
|
5
|
4
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
6
|
2
|
8
|
0
|
0
|
2
|
0
|
|
| Other Current Liabilities |
0
|
5
|
2
|
2
|
2
|
2
|
1
|
|
| Total Current Liabilities |
15
|
29
|
24
|
9
|
10
|
11
|
10
|
|
| Long-Term Debt |
0
|
9
|
11
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
5
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
15
N/A
|
37
+147%
|
40
+7%
|
9
-77%
|
10
+3%
|
11
+15%
|
11
-4%
|
|
| Equity | ||||||||
| Common Stock |
34
|
123
|
139
|
191
|
191
|
200
|
201
|
|
| Retained Earnings |
6
|
9
|
60
|
107
|
135
|
147
|
158
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
28
N/A
|
132
+376%
|
78
-40%
|
83
+6%
|
56
-33%
|
53
-5%
|
43
-19%
|
|
| Total Liabilities & Equity |
43
N/A
|
169
+295%
|
118
-30%
|
92
-22%
|
66
-29%
|
64
-2%
|
54
-16%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
98
|
132
|
156
|
274
|
282
|
401
|
415
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
